Fundamental Analysis (FA)
Framework: DCF Benchmarked
Join Palmy To Bypass The Blur →
For CLII
Valuation Somewhat Weak
43%
Profitability n.A.
Fin. Growth Weak
17%
Leverage & Liquidity Weak
33%
Per Share Metrics Positive
67%
Fin. Health n.A.
Fundamental Analysis (FA)
Benchmarked
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio -1.86 2.93 2.98
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 44.14 7.00 4.85
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value -84.29 0.25 -1.56
Cash -17.52 1.68 2.03
Capex 40.51 -0.20 -0.34
Free Cash Flow 17.91 -0.34 -0.41
Revenue 8.43 0.53 0.49
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin -16.89 0.03 -0.04
Operating Margin 39.30 -0.54 -0.89
ROA 20.64 -0.01 -0.02
ROE 384.63 -0.38 0.08
ROIC 77.88 -0.29 0.16
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of CLII is permitted for members.
5 Growth
The "Growth Entry" for the Focus of CLII is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of CLII is permitted for members.